Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AltheaDx to take DxS K-RAS test to US study centres

This article was originally published in Clinica

Executive Summary

Oncology diagnostics company AltheaDx is set to provide study centres in the US with a K-RAS mutation test kit developed by UK firm DxS for research purposes. An agreement between the two firms will see San Diego, California-based AltheaDx use the test to support clinical research where cancer patients are assessed for their K-RAS mutation status. Manchester-based DxS said that oncologists can use the technology to study patient response to cancer therapies. The test allows clinicians to screen for mutations in the K-RAS gene which is mutated in approximately 35-45% of metastatic colorectal cancer. Financial terms of the agreement were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel